Definium Therapeutics (DFTX) Cash & Equivalents (2022 - 2026)

Definium Therapeutics (DFTX) has 5 years of Cash & Equivalents data on file, last reported at $257.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 210.43% year-over-year to $257.2 million in Q1 2026; TTM through Mar 2026 was $257.2 million, a 210.43% increase from a year earlier, with the FY2025 full-year figure at $255.3 million, down 5.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $257.2 million, up from $255.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for DFTX reached as high as $295.3 million in Q3 2024 and fell as low as $20.0 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $158.8 million across 5 years, with a median of $127.0 million in 2022.
• Across the five-year window, Cash & Equivalents slumped 93.24% in 2025 and surged 210.43% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $131.7 million in 2022, then slipped by 26.58% to $96.7 million in 2023, then soared by 180.77% to $271.5 million in 2024, then slipped by 5.97% to $255.3 million in 2025, then increased by 0.74% to $257.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $257.2 million in Q1 2026, $255.3 million in Q4 2025, and $20.0 million in Q3 2025.